May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab vs. Panretinal Photocoagulation for the Treatment of Proliferative and Severe Non-Proliferative Diabetic Retinopathy: A Contralateral Eye Study
Author Affiliations & Notes
  • G. Garcia-Aguirre
    Retina, Asoc para Evitar la Ceguera, Mexico City, Mexico
  • E. Reyna-Castelán
    Retina, Asoc para Evitar la Ceguera, Mexico City, Mexico
  • M. Torres-Soriano
    Retina, Asoc para Evitar la Ceguera, Mexico City, Mexico
  • V. Kon-Jara
    Retina, Asoc para Evitar la Ceguera, Mexico City, Mexico
  • H. Quiroz-Mercado
    Retina, Asoc para Evitar la Ceguera, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  G. Garcia-Aguirre, None; E. Reyna-Castelán, None; M. Torres-Soriano, None; V. Kon-Jara, None; H. Quiroz-Mercado, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2750. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Garcia-Aguirre, E. Reyna-Castelán, M. Torres-Soriano, V. Kon-Jara, H. Quiroz-Mercado; Intravitreal Bevacizumab vs. Panretinal Photocoagulation for the Treatment of Proliferative and Severe Non-Proliferative Diabetic Retinopathy: A Contralateral Eye Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2750.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the results (visual, electroretinographic, angiographic, complication rate) of bi-monthly intravitreal injection of 2.5 mg of bevacizumab in one eye and of panretinal photocoagulation (PRP) in the contralateral eye of patients with symmetric proliferative (PDR) or severe non-proliferative (SNPDR) diabetic retinopathy, at one-year follow-up.

Methods: : Patients with symmetric PDR or SNPDR without previous treatment were included. In a randomized fashion, one eye underwent PRP (2-3 sessions) and the contralateral eye was treated with 2.5 mg of intravitreal bevacizumab (6 injections in a period of one year). Best corrected visual acuity (BCVA), and OCT were performed at 1, 2, 6 and 12 months. Electroretinogram (ERG) and fluorescein angiogram were performed at baseline, 2 and 6 months.

Results: : Ten patients were included, six of them female, average age 53.3 years. Five had PDR and 5 had SNPDR. At the end of follow-up there was no difference in BCVA. Macular thickness increased significantly in patients treated with PRP vs bevacizumab. Mesopic ERG b-wave decreased significantly in eyes treated with PRP vs bevacizumab. Three eyes treated with PRP developed cystic macular edema, one a vitreous hemorrhage and one a subhyaloid hemorrhage. No complications were observed in eyes treated with bevacizumab.

Conclusions: : Intravitreal bevacizumab was as effective as PRP for the control of PDR and SNPDR at twelve months follow-up, without the adverse effects (increase in macular thickness and decrease in mesopic ERG b-wave) observed with PRP.

Clinical Trial: : www.clinicaltrials.gov NCT00347698

Keywords: diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×